- Home
- BCAL vs AUTL Comparison
BCAL vs AUTL Comparison
Compare BCAL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAL
- AUTL
- Stock Information
- Founded
- BCAL 2001
- AUTL 2014
- Country
- BCAL United States
- AUTL United Kingdom
- Employees
- BCAL N/A
- AUTL N/A
- Industry
- BCAL Major Banks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAL Finance
- AUTL Health Care
- Exchange
- BCAL Nasdaq
- AUTL Nasdaq
- Market Cap
- BCAL 503.4M
- AUTL 590.8M
- IPO Year
- BCAL N/A
- AUTL 2018
- Fundamental
- Price
- BCAL $15.84
- AUTL $1.95
- Analyst Decision
- BCAL Strong Buy
- AUTL Strong Buy
- Analyst Count
- BCAL 1
- AUTL 3
- Target Price
- BCAL $20.00
- AUTL $10.20
- AVG Volume (30 Days)
- BCAL 76.9K
- AUTL 1.2M
- Earning Date
- BCAL 01-29-2025
- AUTL 03-13-2025
- Dividend Yield
- BCAL N/A
- AUTL N/A
- EPS Growth
- BCAL N/A
- AUTL N/A
- EPS
- BCAL 0.22
- AUTL N/A
- Revenue
- BCAL $106,054,000.00
- AUTL $10,091,000.00
- Revenue This Year
- BCAL N/A
- AUTL $851.88
- Revenue Next Year
- BCAL $5.12
- AUTL $220.57
- P/E Ratio
- BCAL $72.00
- AUTL N/A
- Revenue Growth
- BCAL 9.78
- AUTL 82.71
- 52 Week Low
- BCAL $12.30
- AUTL $1.87
- 52 Week High
- BCAL $18.49
- AUTL $6.63
- Technical
- Relative Strength Index (RSI)
- BCAL 45.87
- AUTL 37.49
- Support Level
- BCAL $15.88
- AUTL $1.92
- Resistance Level
- BCAL $16.75
- AUTL $2.15
- Average True Range (ATR)
- BCAL 0.49
- AUTL 0.12
- MACD
- BCAL 0.01
- AUTL 0.01
- Stochastic Oscillator
- BCAL 8.75
- AUTL 22.22
About BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through strong partnerships with its clients.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.